Summary

Location
at Oakland, California and other locations
Dates
study started
study ends around
Principal Investigator
by Hind Al Saif
Headshot of Hind Al Saif
Hind Al Saif

Description

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH

Official Title

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia

Keywords

Hypochondroplasia, vosoritide

Eligibility

You can join if…

  • Participants must have completed the Week 52 visit for 111-303 or 111-212 and have open epiphyses as assessed by left hand antero-posterior (AP) X-rays
  • Parent(s) or guardian(s) must be willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any study-related procedure
  • Females ≥ 10 years old or who have begun menses must have a negative pregnancy test at the Baseline visit and be willing to have additional pregnancy tests during the study
  • If sexually active, participants must be willing to use a highly effective method of contraception while participating in the study
  • Participants are willing and able to perform all study procedures as physically possible
  • Parent(s) or caregiver(s) are willing to administer daily injections to the participants and willing to complete the required training

You CAN'T join if...

  • Permanently discontinued study treatment in the studies 111-303 or 111-212
  • Evidence of decreased growth velocity (AGV < 1.5 cm/year) as assessed over a period of at least 6 months and growth plate closure assessed as per standard of care
  • Taking or planning to take any prohibited medications
  • Planned or expected to have limb-lengthening surgery during the study period
  • Planned or expected bone-related surgery during the study period
  • Require any investigational agent prior to completion of study period
  • Have current malignancy, history of malignancy, or currently under work-up for suspected malignancy
  • Have known hypersensitivity to vosoritide or its excipients
  • Is pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the study
  • Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason

Locations

  • Benioff Children's Hospital - Oakland
    Oakland California 94609 United States
  • Phoenix Children's Hospital - Thomas Campus
    Phoenix Arizona 85016 United States

Lead Scientist at UCSF

  • Hind Al Saif
    Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 13 research publications

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
BioMarin Pharmaceutical
ID
NCT07073014
Phase
Phase 3 Hypochondroplasia Research Study
Study Type
Interventional
Participants
Expecting 140 study participants
Last Updated